Tyrosine Protein Kinase Receptor UFO – Pipeline Review, H2 2019

Global Markets Direct’s, 'Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)- Pipeline Review, H2 2019’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Non Malignant Disorders and Respiratory under development targeting Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

– The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arcus Biosciences Inc

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

F1 Oncology Inc

Genosco Inc

HEC Pharm Co Ltd

Hope Biosciences Inc

Incyte Corp

Konruns Pharmaceutical Co Ltd

Mirati Therapeutics Inc

Novithera SAS

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Symphogen A/S

Takeda Pharmaceutical Co Ltd

TamRx LLC

Tolero Pharmaceuticals Inc

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Overview

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Companies Involved in Therapeutics Development

Arcus Biosciences Inc

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

F1 Oncology Inc

Genosco Inc

HEC Pharm Co Ltd

Hope Biosciences Inc

Incyte Corp

Konruns Pharmaceutical Co Ltd

Mirati Therapeutics Inc

Novithera SAS

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Symphogen A/S

Takeda Pharmaceutical Co Ltd

TamRx LLC

Tolero Pharmaceuticals Inc

Vichem Chemie Research Ltd

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Drug Profiles

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bemcentinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-9016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cabometyx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Arcus Biosciences Inc, H2 2019

Pipeline by Astellas Pharma Inc, H2 2019

Pipeline by BerGenBio ASA, H2 2019

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Pipeline by Celldex Therapeutics Inc, H2 2019

Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Exelixis Inc, H2 2019

Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Pipeline by F1 Oncology Inc, H2 2019

Pipeline by Genosco Inc, H2 2019

Pipeline by HEC Pharm Co Ltd, H2 2019

Pipeline by Hope Biosciences Inc, H2 2019

Pipeline by Incyte Corp, H2 2019

Pipeline by Konruns Pharmaceutical Co Ltd, H2 2019

Pipeline by Mirati Therapeutics Inc, H2 2019

Pipeline by Novithera SAS, H2 2019

Pipeline by Ono Pharmaceutical Co Ltd, H2 2019

Pipeline by Oribase Pharma, H2 2019

Pipeline by Qurient Co Ltd, H2 2019

Pipeline by Rigel Pharmaceuticals Inc, H2 2019

Pipeline by SignalChem Lifesciences Corp, H2 2019

Pipeline by Symphogen A/S, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Pipeline by TamRx LLC, H2 2019

Pipeline by Tolero Pharmaceuticals Inc, H2 2019

Pipeline by Vichem Chemie Research Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports